U.S. Markets closed

Pfizer's Pristiq for major depressive disorder shows positive Phase 4 results

Pfizer announced that a Phase 4 study evaluating the efficacy of Pristiq (desvenlafaxine) Extended Release Tablets met its primary endpoint. The study supports the efficacy of 50 mg/day and 100 mg/day doses of PRISTIQ compared with placebo over eight weeks of treatment in adult patients with major depressive disorder. The most common treatment-emergent adverse events observed were consistent with the known safety and tolerability profile of Pristiq.